» Articles » PMID: 33674619

The Impact of Mammographic Screening on the Subsequent Breast Cancer Risk Associated with Biopsy-proven Benign Breast Disease

Overview
Date 2021 Mar 6
PMID 33674619
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Data on the risk of breast cancer following a benign breast disease (BBD) diagnosis were derived predominantly from populations of women biopsied before the widespread use of mammographic screening and in whom these lesions were mostly incidental findings. Whether or not similar risk associations are seen when these lesions are detected in mammographically screened populations is unknown. To address this, we examined the variation in BBD and breast cancer risk associations by the calendar time of BBD diagnosis (pre- vs. post-mammography era [before vs. 1985 and after]) in a nested case-control study within the Nurses' Health Study (NHS) and NHSII BBD subcohort (488 cases; 1908 controls). We performed logistic regression analysis, adjusting for matching factors and potential confounders, to estimate odds ratio (ORs) and 95% confidence interval (CI) for the association between BBD subtype (non-proliferative, proliferative without atypia, proliferative with atypical hyperplasia (AH)) and subsequent breast cancer risk. When compared with non-proliferative lesions, both proliferative lesions without atypia (PWA) and AHs were associated with similar levels of risk in the pre-mammographic (pre) and post-mammographic (post) time periods (PWA: OR [95% CI] = 1.73 [1.27, 2.36] pre vs. 1.12 [0.73, 1.74] post; AH: 4.41 [2.90, 6.70] pre vs. 3.69 [2.21, 6.15] post). The interaction by mammography era was not statistically significant (p-interaction = 0.47). These results suggest that the risk associations reported for BBD subtypes in the pre-mammography era remain valid for BBD detected after the widespread implementation of mammographic screening.

Citing Articles

A systematic review of determinants of breast cancer risk among women with benign breast disease.

Burke A, ODriscoll J, Abubakar M, Bennett K, Carmody E, Flanagan F NPJ Breast Cancer. 2025; 11(1):16.

PMID: 39955290 PMC: 11829998. DOI: 10.1038/s41523-024-00703-w.


Benign Breast Disease and Breast Cancer Risk in the Percutaneous Biopsy Era.

Sherman M, Vierkant R, Winham S, Vachon C, Carter J, Pacheco-Spann L JAMA Surg. 2023; 159(2):193-201.

PMID: 38091020 PMC: 10719829. DOI: 10.1001/jamasurg.2023.6382.


The impact of mammographic screening on the subsequent breast cancer risk associated with biopsy-proven benign breast disease.

Beca F, Oh H, Collins L, Tamimi R, Schnitt S NPJ Breast Cancer. 2021; 7(1):23.

PMID: 33674619 PMC: 7935945. DOI: 10.1038/s41523-021-00225-9.

References
1.
Collins L, Baer H, Tamimi R, Connolly J, Colditz G, Schnitt S . Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. Cancer. 2006; 109(2):180-7. DOI: 10.1002/cncr.22408. View

2.
Tamimi R, Colditz G, Wang Y, Collins L, Hu R, Rosner B . Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Res Treat. 2011; 128(1):243-50. PMC: 3116083. DOI: 10.1007/s10549-010-1313-1. View

3.
Tyrer J, Duffy S, Cuzick J . A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004; 23(7):1111-30. DOI: 10.1002/sim.1668. View

4.
Tice J, Cummings S, Smith-Bindman R, Ichikawa L, Barlow W, Kerlikowske K . Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med. 2008; 148(5):337-47. PMC: 2674327. DOI: 10.7326/0003-4819-148-5-200803040-00004. View

5.
Beca F, Oh H, Collins L, Tamimi R, Schnitt S . The impact of mammographic screening on the subsequent breast cancer risk associated with biopsy-proven benign breast disease. NPJ Breast Cancer. 2021; 7(1):23. PMC: 7935945. DOI: 10.1038/s41523-021-00225-9. View